Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBPhase 2b trial tests AP01, inhaled pirfenidone, in progressive PF. Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF).
AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease ...
WEB22 hours ago · The results announced last week are from a placebo-controlled Phase 2a study that enrolled 71 IPF patients in China. Patients were randomly assigned to receive a 30 mg dose of the drug once daily ...
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with …
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets …
WEB3 days ago · The FIBRONEER-IPF trial included 1177 participants with IPF across more than 30 countries. They were divided into 3 groups, taking a dose of nerandomilast 9 mg, nerandomilast 18 mg, or placebo twice daily. The primary end point was absolute change in FVC from baseline to week 52. 1. After 52 weeks, patients taking either dose of nerandomilast ...
Experimental anticancer drug shows promise as treatment for …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
FDA Grants Breakthrough Therapy Designation for IPF | Press
WEBFeb 24, 2022 · Ridgefield, Conn. and Ingelheim, Germany, February 24, 2022 – Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF).
Newly Designed Molecule Is Promising Potential Therapy for …
WEBOct 28, 2022 · A team led by Kaminski used a newly designed molecule, called MRG-229, with potential therapeutic implications for IPF. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs. The group published its findings October 17 in eBioMedicine.
Insilico Medicine reports positive Phase IIa | EurekAlert!
WEB4 days ago · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. Positive results ...
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...